<DOC>
	<DOCNO>NCT00832962</DOCNO>
	<brief_summary>The study divide two sub-studies . The first one economical performance comparison two antenatal management strategy RhD negative pregnant woman : first one comprise non invasive RhD fetal type second trimester pregnancy ( GENIFERH 1 RhD type group ) , second conventional management , i.e . without RHD fetal typing ( GENIFERH 1 control group ) . The two group consist 13 maternity ward spread French territory . The second study ( GENIFERH 2 ) evaluation RhD fetal type diagnostic performance biological feasibility routine antenatal practice development know technical support ; base 3500 fetal genotypings perform one year five laboratory participate two study .</brief_summary>
	<brief_title>Routine Fetal RhD Genotyping RhD- Pregnant Women</brief_title>
	<detailed_description>Alloimmunisation RhD ( RH ) red cell surface antigen commonest cause haemolytic disease fetus newborn . It avoid anti D immunoglobulin administration ( RhIg ) . At end year 2005 , new recommendation anti-D prophylaxis France propose RhD negative pregnant woman give anti-D immunoglobulin 28 week ' gestation . However , one third woman would carry RhD negative fetus would receive treatment unnecessarily . A non-invasive fetal RHD type kit , CE label since June 2007 , available could propose RhD negative pregnant woman . Applicable end first trim pregnancy fetal DNA isolate maternal plasma , assay allows RhIg specifically inject unsensitized pregnancy RhD positive fetus , promote use antenatal RhIg prophylaxis rational approach economical ethical impact.The study divide two sub-studies . The first one economical performance comparison two antenatal management strategy RhD negative pregnant woman : first one comprise non invasive RhD fetal type second trimester pregnancy ( GENIFERH 1 RhD type group ) , second conventional management , i.e . without RHD fetal typing ( GENIFERH 1 control group ) . The two group consist 13 maternity ward spread French territory . The second study ( GENIFERH 2 ) evaluation RhD fetal type diagnostic performance biological feasibility routine antenatal practice development know technical support ; base 3500 fetal genotypings perform one year five laboratory participate two study .</detailed_description>
	<criteria>Adult Rh negative pregnant patient ( â‰¥ 18 year ) Valid confirm result Rh D negative status . ( one copy save obstetrical record ) Absence actively produce antiD antibody show laboratory examination blood sample take within first trimester pregnancy . Evolving pregnancy time inclusion study ( 8 26 gestation week confirm early sonography ) . Absence previous invasive fetal RHD genotyping ( chorionic villous sampling , amniocentesis ) . Patient sign informed consent study . Inclusion delivery expect maternity ward Patient affiliate social security regimen . Evolving pregnancy see first time 26 gestation week . Poor understand objective study ( language barrier , ... ) Delivery expect maternity ward participate study . Fetal RHD invasive genotyping perform early pregnancy amniotic fluid chorionic villus .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Rhesus D</keyword>
	<keyword>Anti-D allo-immunization</keyword>
	<keyword>Fetal RHD genotyping</keyword>
	<keyword>anti-D immunoglobulin</keyword>
	<keyword>anti-D prophylaxis</keyword>
</DOC>